CN101091769A - Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method - Google Patents
Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method Download PDFInfo
- Publication number
- CN101091769A CN101091769A CN 200710129917 CN200710129917A CN101091769A CN 101091769 A CN101091769 A CN 101091769A CN 200710129917 CN200710129917 CN 200710129917 CN 200710129917 A CN200710129917 A CN 200710129917A CN 101091769 A CN101091769 A CN 101091769A
- Authority
- CN
- China
- Prior art keywords
- medicine
- gastric cancer
- hours
- esophageal carcinoma
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medicine for preventing and curing carcinoma of esophagus and carcinoma of stomach with obvious therapeutic effect. It is made up by using 13 Chinese medicinal materials of isatis leaf, ganoderma, cordyceps, saffron, coptis root and others through a certain preparation process.
Description
One, technical field
The present invention relates to medicine of a kind of treatment and prevention esophageal carcinoma, gastric cancer and preparation method thereof, more particularly relating to a kind of is that medicine of esophageal carcinoma, gastric cancer and preparation method thereof is treated and prevented to raw material with Chinese medicine.
Two, background technology
Esophageal carcinoma, gastric cancer are one of higher malignant tumor of sickness rate in the world, also are a kind of cancer that occupies first of the mortality rate in China.Although present developing rapidly along with multiple treatment means such as surgical operation, X ray, radiosiotope, fast neutron, laser, freezing and targeting therapy, immunotherapy and method, improved clinical therapeutic efficacy greatly, but most of patients treats to have lost when clinical diagnosis is clear and definite the best opportunity of operative treatment, can only take non-operative treatment.And modern medicine X-ray therapy common at present and that extensively adopt and chemical medicinal treatment are to the bone marrow immunologic function, and liver, renal function and gastral influence and side effect are bigger, cause many patients to be difficult to accept.
How on the books the traditional medicine of China is also to this disease, belongs to the scope of " gastric abscess ", " regurgitation ", " dysphagia " diseases such as " note of the ancient Chinese are long-pending ".The compositions that constitutes with natural drug or its extract component is the Chinese traditional medicine of feature, has also demonstrated the distinct advantages that has aspect many on the treatment cancer, and constantly has been studied and is developing.In these medicines, the applicable medicine that comprises the anti-multiple cancerous protuberance of gastric cancer is arranged, composition is comparatively numerous and jumbled usually, and generally often not ideal enough at the therapeutic effect of specific gastric cancer.Other has a class is the medicine that is exclusively used in treatment digestive tract or gastric cancer, as the report of " the Shanxi traditional Chinese medical science " 1993 (5) about " ginseng river oral liquid " of treatment digestive tract tumor, and the relevant medicine reported of document such as Chinese patent 94103658.8,94104935.3,93121390.8.These medicines are except that from the theoretical treatment rule of Chinese medicine is not the same, an one common feature is that also the medicine composition is all comparatively complicated, some also contains the chemicals composition simultaneously, or also needs and the same usefulness of 5-fluorouracil (5-Fu), thereby satisfied inadequately part is still arranged.
Three, summary of the invention
One of purpose of the present invention provides a kind of treatment and prevents the medicine of esophageal carcinoma, gastric cancer.
The preparation method that two of purpose of the present invention provides a kind of treatment and prevents the medicine of esophageal carcinoma, gastric cancer.
This and other purpose of the present invention will further embody and set forth by following detailed description and explanation.
The medicine of treatment of the present invention and prevention esophageal carcinoma, gastric cancer is the medicament of being made by the raw material of following weight portion:
Folium Isatidis 10-50 hides Ganoderma 20-60 Cordyceps 1-10
Stigma Croci 20-50 Rhizoma Coptidis 20-60 Fructus Trichosanthis 20-30
The refined 20-50 of Herba Scutellariae Barbatae 20-30 Herba Lobeliae Chinensis 20-30 Semen Phaseoli
CAOHECHE 20-30 Radix Sophorae Tonkinensis 10-30 Herba Taraxaci 30-50
Rhizoma Paridis 10-20.
Further, the medicine of treatment of the present invention and prevention esophageal carcinoma, gastric cancer, the weight portion of each raw material is:
Folium Isatidis 15-40 hides Ganoderma 25-50 Cordyceps 2-8
Stigma Croci 25-40 Rhizoma Coptidis 25-50 Fructus Trichosanthis 20-30
The refined 20-40 of Herba Scutellariae Barbatae 25-30 Herba Lobeliae Chinensis 20-30 Semen Phaseoli
CAOHECHE 25-30 Radix Sophorae Tonkinensis 15-30 Herba Taraxaci 30-40
Rhizoma Paridis 15-20
What can select is, the medicine of treatment of the present invention and prevention esophageal carcinoma, gastric cancer, and the weight portion of each raw material is:
Folium Isatidis 20-30 hides Ganoderma 25-40 Cordyceps 2-6
Stigma Croci 25-35 Rhizoma Coptidis 25-35 Fructus Trichosanthis 20-30
The refined 20-30 of Herba Scutellariae Barbatae 25-30 Herba Lobeliae Chinensis 20-30 Semen Phaseoli
CAOHECHE 25-30 Radix Sophorae Tonkinensis 15-20 Herba Taraxaci 30-40
Rhizoma Paridis 15-20
In the medicine of treatment of the present invention and prevention esophageal carcinoma, gastric cancer, described medicament is the above a dosage form of any pharmaceutics.Be preferably oral liquid.
The preparation method of the medicine of treatment of the present invention and prevention esophageal carcinoma, gastric cancer, be through flushing with clean water, section and pulverizing with above-mentioned Chinese medicine, put into extraction pot then, by solid-to-liquid ratio 1: 5-15 puts into water, through 100 ℃ of steaming and decocting 1.5-3 hours, filter, get and filter the back liquid cools and sealed in 24 hours.
What can select is, in the preparation method of the medicine of treatment of the present invention and prevention esophageal carcinoma, gastric cancer, with above-mentioned Chinese medicine through flushing with clean water, section and pulverizing, put into extraction pot then, by solid-to-liquid ratio 1: 8-10 puts into water, through 100 ℃ of steaming and decocting 1.5-2 hours, filter, get and filter the back liquid cools and sealed in 24 hours.
Be preferably, in the preparation method of the medicine of treatment of the present invention and prevention esophageal carcinoma, gastric cancer, with above-mentioned Chinese medicine through flushing with clean water, section and pulverizing, put into extraction pot then, by solid-to-liquid ratio 1: 5-10 puts into water, through 100 ℃ of steaming and decocting 1.5-2 hours, filter time filtrate of winning, extract once more, by solid-to-liquid ratio 1: 3-5 puts into water, through 100 ℃ of steaming and decocting 0.5-1 hours, filter, filtrate for the second time, merge secondary filter liquid, cool off and sealed in 24 hours.
The medicine, particularly oral liquid of treatment of the present invention and prevention esophageal carcinoma, gastric cancer have heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, get rid of vivotoxin, strengthen autoimmune, kill effects such as tumor and cancerous cell.
Medicine of the present invention shows that through clinical use result following advantage is arranged:
1, the present invention selects conventional Chinese medicine for use, and medicine source abundance, each component are that pharmacopeia is contained, meets the pharmaceutical control law regulation.
2, the present invention is an oral liquid, need not decoct medicine mildly bitter flavor, taking convenience.
3, both can use separately, can cooperate chemicotherapy again, can potentiation, can alleviate the chemicotherapy toxicity again, the quality of making the life better prolongs life cycle.
4, inexpensive.
5, treatment and prevent two kinds of effects can be arranged.
Below further specify the present invention by specific embodiment, but embodiment only be used for the explanation, can not limit the scope of the invention.
In the present invention, if not refer in particular to, all parts, amount, percentage ratio are unit of weight, and all raw materials all can be buied from market.
Four, the specific embodiment
Embodiment 1
Take by weighing raw material by following proportioning:
Folium Isatidis 15 grams are hidden Ganoderma 25 grams, Cordyceps 2 grams, and Stigma Croci 25 grams,
Rhizoma Coptidis 25 grams, Fructus Trichosanthis 20 grams, Herba Scutellariae Barbatae 20 grams, Herba Lobeliae Chinensis 20 grams
Refined 25 grams of Semen Phaseoli, CAOHECHE 20 grams, Radix Sophorae Tonkinensis 12 grams, Herba Taraxaci 30 grams
Rhizoma Paridis 10 grams.
Extraction pot is put in above-mentioned Chinese medicine is clean through flushing with clean water, section and pulverizing then, puts into water (deionized water) at 1: 6 by solid-to-liquid ratio, through 100 ℃ of steaming and decoctings 2 hours, filter, get filter after liquid cools sealed in 24 hours.
Embodiment 2
Take by weighing raw material by following proportioning:
Folium Isatidis 45 grams are hidden Ganoderma 55 grams, Cordyceps 8 grams, and Stigma Croci 45 grams,
Rhizoma Coptidis 60 grams, Fructus Trichosanthis 30 grams, Herba Scutellariae Barbatae 30 grams, Herba Lobeliae Chinensis 30 grams
Refined 45 grams of Semen Phaseoli, CAOHECHE 30 grams, Radix Sophorae Tonkinensis 30 grams, Herba Taraxaci 50 grams
Rhizoma Paridis 20 grams.
Above-mentioned Chinese medicine through flushing with clean water, section and pulverizing, is put into extraction pot then, put into water at 1: 10, through 100 ℃ of steaming and decoctings 1.5 hours, filter, get and filter the back liquid cools and sealed in 24 hours by solid-to-liquid ratio.
Embodiment 3
Take by weighing raw material by following proportioning:
Folium Isatidis 30 grams are hidden Ganoderma 25 grams, Cordyceps 5 grams, and Stigma Croci 35 grams,
Rhizoma Coptidis 35 grams, Fructus Trichosanthis 25 grams, Herba Scutellariae Barbatae 25 grams, Herba Lobeliae Chinensis 25 grams
Refined 30 grams of Semen Phaseoli, CAOHECHE 30 grams, Radix Sophorae Tonkinensis 20 grams, Herba Taraxaci 30 grams
Rhizoma Paridis 20 grams.
With above-mentioned Chinese medicine through flushing with clean water, section and pulverizing, put into extraction pot then, put into water at 1: 5 by solid-to-liquid ratio, through 100 ℃ of steaming and decoctings 1.5 hours, filtration, time filtrate of winning, extract once more, put into water at 1: 4 by solid-to-liquid ratio,, get filtrate for the second time through 100 ℃ of steaming and decoctings 1 hour, filtration, merge secondary filter liquid, cool off and sealed in 24 hours.
Embodiment 4
Further verify this prescription in vital energy benefiting and the kidney invigorating by in-vitro pharmacological experiments, the effect of immunostimulant aspect:
1, animal: this laboratory animal is the NIH mice, provides (Yun Weidong manages A12 number) by Yunnan Province natural drug pharmacology key lab.
2, method and result: select the 18-20gNIH mice for use, be divided into 5 groups at random, be respectively blank group (0.5% sodium carboxymethyl cellulose 25ml/kg), pharmaceutical composition (3g/kg).Gastric infusion, 9d continuously.
One, to normal mouse immune organ weight's influence
2d after this administration of end puts to death mice, wins thymus, spleen, claims weight in wet base, and calculates acropetal coefficient's (g/10g body weight).The results are shown in Table 1.
Table 1 drug regimen of the present invention is to the influence of normal mouse immune organ
P＜0.01, in the blank group relatively.
Last table result shows that drug regimen of the present invention can have the obvious suppression effect to normal mouse thymus.
Two, to the delayed hypersensitivity of 2,4 dinitrochlorobenzene induced mice
With 1.25% dinitro-chlorine propiophenone in 0.02ml/ sensitization of mouse back subcutaneous injection, 2d begins administration, 10d is with in the middle of the right foot pad of 0.25% dinitro-chlorine propiophenone subcutaneous injection mice, 0.02ml/ only, the acetone solution of parapodum being injected same volume compares, and puts to death mice after 38 hours, cut two foots from ankle, weight difference with two foots is the swelling degree, carries out statistical procedures, the results are shown in Table 2.
Table 2 drug regimen of the present invention is to the influence of dinitrochlorobenzene induced mice delayed hypersensitivity
Compare with the blank group P＜0.05.
Last table result shows that the present composition has significant inhibitory effect to the delayed hypersensitivity of dinitrochlorobenzene induced mice.
Three, carbon clearance test
30min after administration injects india ink 0.1ml/10g body weight from mouse tail vein, in the 2nd and during 10min respectively the eye socket vein get blood 20 μ l, put into the 3ml distilled water, in 680nm place survey absorbance, dissect liver, spleen simultaneously, weigh.Be calculated as follows and clean up index (k), phagocytic index.The results are shown in Table 3.
Table 3 present composition is to the influence of mice reticuloendothelial system phagocytic function
K=(logA2-logA10)/(t10-t2); α=3k * body weight/(liver weight+spleen is heavy)
Last result shows that the present composition can significantly improve clearance in mice exponential sum phagocytic index.
Embodiment 5
The present invention that tumour hospital uses preparation in the institute treats patients with gastric cancer 106 examples, and adopts WENWEISHU JIAONANG to do contrast, the result: total effective rate treatment group and matched group relatively have significant difference (P＞0.05), and the treatment group obviously is better than matched group.Now be summarized as follows:
1, physical data: select to have typical clinical symptom and make a definite diagnosis patients with gastric cancer 136 examples through gastroscope and pathology, be divided into 2 groups at random, 106 examples are organized in treatment, male 75 examples, and women 31 examples, the oldest 65 years old, minimum 28 years old, the course of disease is the longest 15 years, and was the shortest 6 months.Matched group 30 examples, male 23 examples, women 7 examples, the oldest 63 years old, minimum 32 years old, the course of disease is the longest 10 years, and was the shortest 8 months.Two groups of there was no significant differences (P＞0.05) such as the patient age course of disease have comparability.
2, Therapeutic Method: treatment group: each 100 milliliters of oral stomach oxazepan oral liquid, 3 times on the 1st; Matched group: each 3 of oral WENWEISHU Yiganning capsule (the refreshing Radix et rhizoma smilacinae japonicae in Hefei factory produces), 2 times on the 1st.Two groups was 1 course of treatment with 1 month all, all inactive other medicines of period in a medicine, and be careful in one's diet, avoid direct stimulation.
3, therapeutic outcome: through treating 1 course of treatment, the result compares: treatment total effective rate and matched group are than imitating, and two groups have significant difference, and the treatment group obviously is better than matched group, sees Table 5.
Table 4 liang group therapeutic outcome relatively
Group example number is cured invalid total effective rate (%) the P value that takes a turn for the better
Treatment organizes 106 73 23 10 90.6
＜0.05
Matched group 30 13 98 73.3
4, conclusion
By clinical observation on the therapeutic effect, the present invention is used for the treatment of gastric cancer, and clinical total effective rate is 88.7%, its curative effect is better than similar other Chinese patent medicine, and should enrich in medicine source, side, and is cheap, taking convenience can be accepted by extensive patients, will produce very big clinical value and economic benefit.
Embodiment 5
In therapeutic process, what effect was the fastest is Yang Huaiqing, and he suffers from gastrocolonic cancer.After hospital gives and operates on, find that colon has covered with tumor, can't treat that sewed on again, the notice of being critically ill is down to family members.In this case, clothes the present invention treatment and prevention esophagus cancer and stomach cancer oral liquid, every day 4 times, each 100 milliliters, after 3 days, the stomach colon is all unobstructed, can be free movable after 20 days, all are normal for gastrointestinal tract after 3 months.
What curative effect was best is Tongshan County Hong Lou village, Jiangsu Province flood gram justice, this patient makes a definite diagnosis " stomach angle cancer " through each 100 milliliters of clothes the present invention treatment and prevention esophagus cancer and stomach cancer oral liquid every day 4 times through Tongshan County the 3rd the People's Hospital, taking medicine 30 days, all are normal after Beijing 301 Hospital checks.
Curative effect the best be easy village paddy show of big week of Tong County, Beijing orchid, through Beijing Tongren Hospital make a definite diagnosis " esophagus stage casing isolatism phlebangioma, chronic superficial gastritis companion is rotten to the corn; The expert can not perform the operation, and obeys the present invention's treatment and prevention esophagus cancer and stomach cancer oral liquid 3 wheat harvesting periods in this case, and all are normal now.
Claims (8)
1, the medicine of a kind of treatment and prevention esophageal carcinoma, gastric cancer is characterized in that it is the medicament of being made by the raw material of following weight portion:
Folium Isatidis 10-50 hides Ganoderma 20-60 Cordyceps 1-10
Stigma Croci 20-50 Rhizoma Coptidis 20-60 Fructus Trichosanthis 20-30
The refined 20-50 of Herba Scutellariae Barbatae 20-30 Herba Lobeliae Chinensis 20-30 Semen Phaseoli
CAOHECHE 20-30 Radix Sophorae Tonkinensis 10-30 Herba Taraxaci 30-50
Rhizoma Paridis 10-20.
2, the medicine of treatment according to claim 1 and prevention esophageal carcinoma, gastric cancer is characterized in that the weight portion of each raw material is:
Folium Isatidis 15-40 hides Ganoderma 25-50 Cordyceps 2-8
Stigma Croci 25-40 Rhizoma Coptidis 25-50 Fructus Trichosanthis 20-30
The refined 20-40 of Herba Scutellariae Barbatae 25-30 Herba Lobeliae Chinensis 20-30 Semen Phaseoli
CAOHECHE 25-30 Radix Sophorae Tonkinensis 15-30 Herba Taraxaci 30-40
Rhizoma Paridis 15-20.
3, the medicine of treatment according to claim 1 and prevention esophageal carcinoma, gastric cancer is characterized in that the weight portion of each raw material is:
Folium Isatidis 20-30 hides Ganoderma 25-40 Cordyceps 2-6
Stigma Croci 25-35 Rhizoma Coptidis 25-35 Fructus Trichosanthis 20-30
The refined 20-30 of Herba Scutellariae Barbatae 25-30 Herba Lobeliae Chinensis 20-30 Semen Phaseoli
CAOHECHE 25-30 Radix Sophorae Tonkinensis 15-20 Herba Taraxaci 30-40
Rhizoma Paridis 15-20.
4,, it is characterized in that described medicament is the above a dosage form of any pharmaceutics according to the medicine of the described treatment of one of claim 1-3 and prevention esophageal carcinoma, gastric cancer.
5, the medicine of treatment according to claim 4 and prevention esophageal carcinoma, gastric cancer is characterized in that described dosage form is an oral liquid.
6, according to the preparation method of the medicine of the described treatment of one of claim 1-5 and prevention esophageal carcinoma, gastric cancer, it is characterized in that above-mentioned Chinese medicine through flushing with clean water, section and pulverizing, put into extraction pot then, by solid-to-liquid ratio 1: 5-15 puts into water, through 100 ℃ of steaming and decocting 1.5-3 hours, filter, get and filter the back liquid cools and sealed in 24 hours.
7, the preparation method of the medicine of treatment according to claim 6 and prevention esophageal carcinoma, gastric cancer, it is characterized in that above-mentioned Chinese medicine through flushing with clean water, section and pulverizing, put into extraction pot then, by solid-to-liquid ratio 1: 8-10 puts into water, through 100 ℃ of steaming and decocting 1.5-2 hours, filter, get and filter the back liquid cools and sealed in 24 hours.
8, the preparation method of the medicine of treatment according to claim 6 and prevention esophageal carcinoma, gastric cancer, it is characterized in that just above-mentioned Chinese medicine through flushing with clean water, section and pulverizing, puts into extraction pot then, by solid-to-liquid ratio 1: 5-10 puts into water, through 100 ℃ of steaming and decocting 1.5-2 hours, filtration, win time filtrate extracts once more, and by solid-to-liquid ratio 1: 3-5 puts into water, through 100 ℃ of steaming and decocting 0.5-1 hours, filtration, filtrate for the second time, merge secondary filter liquid, cool off and sealed in 24 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101299171A CN101091769B (en) | 2007-07-20 | 2007-07-20 | Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101299171A CN101091769B (en) | 2007-07-20 | 2007-07-20 | Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101091769A true CN101091769A (en) | 2007-12-26 |
| CN101091769B CN101091769B (en) | 2010-06-02 |
Family
ID=38990326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101299171A Active CN101091769B (en) | 2007-07-20 | 2007-07-20 | Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101091769B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104667002A (en) * | 2015-03-10 | 2015-06-03 | 济南骄泰信息技术有限公司 | Medicine for treating stomach cancer |
| CN105395698A (en) * | 2015-12-30 | 2016-03-16 | 青岛昌安达药业有限公司 | Traditional Chinese medicine composition for treating stomach cancer |
| CN105833225A (en) * | 2016-05-11 | 2016-08-10 | 张士舜 | Traditional Chinese medicine composition for treating stomach cancer and preparation method thereof |
| CN107296901A (en) * | 2017-06-15 | 2017-10-27 | 合肥川迪医药技术有限公司 | A kind of anti-tumor Chinese medicine and preparation method thereof |
| CN108096440A (en) * | 2017-12-29 | 2018-06-01 | 缪荣明 | A kind of Chinese medicine composition with multiple detoxicating functions and preparation method thereof |
| CN108686118A (en) * | 2018-06-27 | 2018-10-23 | 桐城市泰安中药材种植专业合作社 | A kind of health anticancer health-care product and preparation method thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1186687A (en) * | 1997-10-06 | 1998-07-08 | 陈创 | Cancer preventing curing medicine series and its preparation |
| CN1084206C (en) * | 1999-05-20 | 2002-05-08 | 周金龙 | Cancer treating medicine and its preparation |
| CN1336186A (en) * | 2000-07-28 | 2002-02-20 | 雷学军 | Antineoplastic functional water containing natural medicine component and its compounding process |
| CN1408383A (en) * | 2001-09-27 | 2003-04-09 | 张丽 | Pure traditional Chinese medicine preparation for curing gastroinstestinal cancer and preparing method |
| CN100400088C (en) * | 2004-05-28 | 2008-07-09 | 张海峰 | Anticancer medicine |
| CN100546586C (en) * | 2006-10-12 | 2009-10-07 | 宁波泰康红豆杉生物工程有限公司 | The application of yew amylose in pharmacy |
-
2007
- 2007-07-20 CN CN2007101299171A patent/CN101091769B/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104667002A (en) * | 2015-03-10 | 2015-06-03 | 济南骄泰信息技术有限公司 | Medicine for treating stomach cancer |
| CN105395698A (en) * | 2015-12-30 | 2016-03-16 | 青岛昌安达药业有限公司 | Traditional Chinese medicine composition for treating stomach cancer |
| CN105833225A (en) * | 2016-05-11 | 2016-08-10 | 张士舜 | Traditional Chinese medicine composition for treating stomach cancer and preparation method thereof |
| CN107296901A (en) * | 2017-06-15 | 2017-10-27 | 合肥川迪医药技术有限公司 | A kind of anti-tumor Chinese medicine and preparation method thereof |
| CN108096440A (en) * | 2017-12-29 | 2018-06-01 | 缪荣明 | A kind of Chinese medicine composition with multiple detoxicating functions and preparation method thereof |
| CN108686118A (en) * | 2018-06-27 | 2018-10-23 | 桐城市泰安中药材种植专业合作社 | A kind of health anticancer health-care product and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101091769B (en) | 2010-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258563B (en) | Anti-cancer medicinal composition and Chinese medicinal composition | |
| CN102058767B (en) | Chinese medicine for treating senile chronic bronchitis and method for preparing pills thereof | |
| CN101181529B (en) | Chinese medicine composition for curing tumor and preparation method thereof | |
| CN101091769B (en) | Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method | |
| CN103007206A (en) | Oral liquid for treating chronic atrophic gastritis | |
| CN101491663A (en) | Traditional Chinese medicine composition for treating various cancer | |
| CN103520395B (en) | Traditional Chinese medicine composition for treating lung cancer | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN1305515C (en) | Chinese medicinal powder and decoction composition for treating cancer | |
| CN1883640A (en) | Medicine for treating leucocytopenia caused after tumor radiotherapy and chemotherapy | |
| CN101007159B (en) | Traditional Chinese medicine for preventing and controlling tumor | |
| CN103223149B (en) | Chinese herb medicine composition for treating lung cancer | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN104189781A (en) | Pharmaceutical composition for treating neuroglioma | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN101810667A (en) | Medicine composition for auxiliary treatment of cancer | |
| CN106581299B (en) | Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof | |
| CN103536879A (en) | Pharmaceutical composition for treating diabetes mellitus and preparation method thereof | |
| CN104147254A (en) | Traditional Chinese medicine preparation for treating leucocytopenia after chemotherapy | |
| CN103263580A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN104524359B (en) | A kind of Chinese medicine composition, its preparation method and application | |
| CN103263595A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN1931285B (en) | Chinese medicine composition and its preparation process | |
| CN114404490B (en) | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method | |
| CN1194717C (en) | Snake poison capsule for treating lung cancer and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |